LncRNA GACAT3: A Promising Biomarker and Therapeutic Target in Human Cancers

Xin Yuan; Zihui Dong; Shen Shen

doi:10.3389/fcell.2022.785030

LncRNA GACAT3: A Promising Biomarker and Therapeutic Target in Human Cancers

Front Cell Dev Biol. 2022 Jan 20:10:785030. doi: 10.3389/fcell.2022.785030. eCollection 2022.

Authors

Xin Yuan¹, Zihui Dong^{1

2}, Shen Shen^{1

2}

Affiliations

¹ Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² Precision Medicine Center, Gene Hospital of Henan Province, The First Affifiliated Hospital of Zhengzhou University, Zhengzhou, China.

Abstract

Long non-coding RNAs (lncRNAs) are a class of functional RNA molecules that do not encode proteins and are composed of more than 200 nucleotides. LncRNAs play important roles in epigenetic and gene expression regulation. The oncogenic lncRNA GACAT3 was recently discovered to be dysregulated in many tumors. Aberrant expression of GACAT3 contributes to clinical characteristics and regulates multiple oncogenic processes. The association of GACAT3 with a variety of tumors makes it a promising biomarker for diagnosis, prognosis, and targeted therapy. In this review, we integrate the current understanding of the pathological features, biological functions, and molecular mechanisms of GACAT3 in cancer. Additionally, we provide insight into the utility of GACAT3 as an effective diagnostic and prognostic marker for specific tumors, which offers novel opportunities for targeted therapeutic intervention.

Keywords: GACAT3; biomarker; cancer; lncRNA; molecular mechanisms.

Publication types

Review